GlassScriptPhysician profile
Bridget Burruano
NPI 1225059678
$5,375.67
in general payments reported to CMS, 2019-2025
21 companies · $3,912 in 2025
The $3,912 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $51.20 · 2023: $197 · 2024: $1,084 · 2025: $3,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,035 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,034.62 |
| Education | $158.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $975.08 | 2023-2025 | |
| Pfizer INC. | $751.60 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $506.41 | 2024-2025 | Dupixent, Libtayo |
| Ucb, INC. | $413.01 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $322.57 | 2024-2025 | |
| Genzyme Corporation | $322.16 | 2024-2025 | |
| Medtronic, INC. | $311.53 | 2021-2025 | Venaseal |
| Galderma Laboratories, L.P. | $308.14 | 2021-2025 | Nemluvio |
| Janssen Biotech, INC. | $244.26 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $215.52 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $208.96 | 2024-2025 | Sotyktu |
| Incyte Corporation | $184.52 | 2024-2025 | Opzelura |
| Amgen INC. | $167.11 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $104.35 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Organon LLC | $101.38 | 2025 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $91.29 | 2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $39.47 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.02 | 2024 | Spevigo |
| Allergan, INC. | $29.10 | 2022 | |
| Merz North America, INC. | $22.89 | 2021 | |
| Pinnacle Biologics, INC | $22.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Burruano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.